Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apyx Medical (APYX) Change in Cash (2016 - 2025)

Apyx Medical's Change in Cash history spans 15 years, with the latest figure at $6.6 million for Q4 2025.

  • For Q4 2025, Change in Cash rose 77.17% year-over-year to $6.6 million; the TTM value through Dec 2025 reached -$1000.0, up 99.99%, while the annual FY2025 figure was -$1000.0, 99.99% up from the prior year.
  • Change in Cash reached $6.6 million in Q4 2025 per APYX's latest filing, up from -$4.2 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $21.5 million in Q4 2023 to a low of -$6.4 million in Q1 2024.
  • Average Change in Cash over 5 years is -$508750.0, with a median of -$3.1 million recorded in 2021.
  • Peak YoY movement for Change in Cash: plummeted 16475.0% in 2022, then surged 563.65% in 2023.
  • A 5-year view of Change in Cash shows it stood at -$28000.0 in 2021, then tumbled by 16475.0% to -$4.6 million in 2022, then soared by 563.65% to $21.5 million in 2023, then tumbled by 82.67% to $3.7 million in 2024, then surged by 77.17% to $6.6 million in 2025.
  • Per Business Quant, the three most recent readings for APYX's Change in Cash are $6.6 million (Q4 2025), -$4.2 million (Q3 2025), and -$1.7 million (Q2 2025).